Gys1 antisense therapy rescues neuropathological bases of murine Lafora disease
- PMID: 33993268
- PMCID: PMC8634080
- DOI: 10.1093/brain/awab194
Gys1 antisense therapy rescues neuropathological bases of murine Lafora disease
Abstract
Lafora disease is a fatal progressive myoclonus epilepsy. At root, it is due to constant acquisition of branches that are too long in a subgroup of glycogen molecules, leading them to precipitate and accumulate into Lafora bodies, which drive a neuroinflammatory response and neurodegeneration. As a potential therapy, we aimed to downregulate glycogen synthase, the enzyme responsible for glycogen branch elongation, in mouse models of the disease. We synthesized an antisense oligonucleotide (Gys1-ASO) that targets the mRNA of the brain-expressed glycogen synthase 1 gene (Gys1). We administered Gys1-ASO by intracerebroventricular injection and analysed the pathological hallmarks of Lafora disease, namely glycogen accumulation, Lafora body formation, and neuroinflammation. Gys1-ASO prevented Lafora body formation in young mice that had not yet formed them. In older mice that already exhibited Lafora bodies, Gys1-ASO inhibited further accumulation, markedly preventing large Lafora bodies characteristic of advanced disease. Inhibition of Lafora body formation was associated with prevention of astrogliosis and strong trends towards correction of dysregulated expression of disease immune and neuroinflammatory markers. Lafora disease manifests gradually in previously healthy teenagers. Our work provides proof of principle that an antisense oligonucleotide targeting the GYS1 mRNA could prevent, and halt progression of, this catastrophic epilepsy.
Keywords: Lafora disease; antisense oligonucleotides; glycogen synthase; neuroinflammation; therapy.
© The Author(s) (2021). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please email: [email protected].
Figures




Similar articles
-
Gys1 Antisense Therapy Prevents Disease-Driving Aggregates and Epileptiform Discharges in a Lafora Disease Mouse Model.Neurotherapeutics. 2023 Oct;20(6):1808-1819. doi: 10.1007/s13311-023-01434-9. Epub 2023 Sep 12. Neurotherapeutics. 2023. PMID: 37700152 Free PMC article.
-
An inducible glycogen synthase-1 knockout halts but does not reverse Lafora disease progression in mice.J Biol Chem. 2021 Jan-Jun;296:100150. doi: 10.1074/jbc.RA120.015773. Epub 2020 Dec 10. J Biol Chem. 2021. PMID: 33277363 Free PMC article.
-
Targeting Gys1 with AAV-SaCas9 Decreases Pathogenic Polyglucosan Bodies and Neuroinflammation in Adult Polyglucosan Body and Lafora Disease Mouse Models.Neurotherapeutics. 2021 Apr;18(2):1414-1425. doi: 10.1007/s13311-021-01040-7. Epub 2021 Apr 8. Neurotherapeutics. 2021. PMID: 33830476 Free PMC article.
-
Role of Astrocytes in the Pathophysiology of Lafora Disease and Other Glycogen Storage Disorders.Cells. 2023 Feb 24;12(5):722. doi: 10.3390/cells12050722. Cells. 2023. PMID: 36899857 Free PMC article. Review.
-
Glycogen in Astrocytes and Neurons: Physiological and Pathological Aspects.Adv Neurobiol. 2019;23:311-329. doi: 10.1007/978-3-030-27480-1_10. Adv Neurobiol. 2019. PMID: 31667813 Free PMC article. Review.
Cited by
-
Implications of a De Novo Variant in the SOX12 Gene in a Patient with Generalized Epilepsy, Intellectual Disability, and Childhood Emotional Behavioral Disorders.Curr Issues Mol Biol. 2024 Jun 26;46(7):6407-6422. doi: 10.3390/cimb46070383. Curr Issues Mol Biol. 2024. PMID: 39057025 Free PMC article.
-
A Review of Targeted Therapies for Monogenic Epilepsy Syndromes.Front Neurol. 2022 Feb 17;13:829116. doi: 10.3389/fneur.2022.829116. eCollection 2022. Front Neurol. 2022. PMID: 35250833 Free PMC article. Review.
-
Natural history of Lafora disease: a prognostic systematic review and individual participant data meta-analysis.Orphanet J Rare Dis. 2021 Aug 16;16(1):362. doi: 10.1186/s13023-021-01989-w. Orphanet J Rare Dis. 2021. PMID: 34399803 Free PMC article.
-
Lack of p62 Impairs Glycogen Aggregation and Exacerbates Pathology in a Mouse Model of Myoclonic Epilepsy of Lafora.Mol Neurobiol. 2022 Feb;59(2):1214-1229. doi: 10.1007/s12035-021-02682-6. Epub 2021 Dec 28. Mol Neurobiol. 2022. PMID: 34962634 Free PMC article.
-
Glycogen synthase downregulation rescues the amylopectinosis of murine RBCK1 deficiency.Brain. 2022 Jul 29;145(7):2361-2377. doi: 10.1093/brain/awac017. Brain. 2022. PMID: 35084461 Free PMC article.
References
-
- Roach PJ. Glycogen and its metabolism. Curr Mol Med. 2002;2(2):101–120. - PubMed
-
- Ganesh S, Delgado-Escueta AV, Sakamoto T, et al.Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice. Hum Mol Genet. 2002;11(11):1251–1262. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials